Arterial blood vessel supplying benign tumor

Arterial blood vessels supplying benign tumors refers to the arteries that provide blood flow to regions of benign tumor tissue. In oncology and vascular biology, the focus is usually on the molecular drivers of blood vessel formation (angiogenesis), especially in malignant tumors. Benign tumors generally receive blood through pre-existing or mildly remodeled vessels; they do not typically exhibit the severe vascular abnormalities, structural chaos, or pronounced neoangiogenesis observed in malignant tumors[1][2][4]. Therapeutic strategies in cancer often target molecules such as Vascular endothelial growth factor (VEGF) that drive new vessel growth (angiogenesis), rather than the arteries themselves[3][4]. There are no canonical molecular targets or approved drugs that directly and specifically target the arteries supplying benign tumors. In cases where reduction of blood supply to benign tumors is necessary (such as for surgical management or embolization), interventions are anatomical (e.g., arterial embolization), not molecular[4]. If you are seeking molecular targets related to tumor blood vessels generally, consider querying for targets such as Vascular endothelial growth factor receptor (VEGF receptor), Angiopoietin receptor, or Platelet-derived growth factor receptor (PDGFR)—all of which are canonical targets in therapeutic angiogenesis inhibition[3][4].